Loading...
Market
Primary side effect reported for Cobenfy (KarXT) by end of 2024?
2
Resolution / Starting Odds
Dry mouth • 25%
Drowsiness • 25%
Nausea • 25%
Other • 25%
FDA adverse event reporting system, Bristol Myers Squibb official reports, major pharmaceutical news outlets
Story
FDA Approves Bristol Myers' Cobenfy (KarXT), First New Schizophrenia Drug in Seven Decades
Sep 26, 2024, 10:52 PM
The U.S. Food and Drug Administration has approved Cobenfy (KarXT), a new schizophrenia drug developed by Karuna Therapeutics and acquired by Bristol Myers Squibb in a $14 billion deal. This marks the first new type of treatment for the mental disorder since the 1950s. Cobenfy acts on M1/M4 muscarinic acetylcholine receptors, expanding the treatment landscape beyond traditional dopamine-targeted medications. The twice-daily oral pill appears to be effective in reducing symptoms of schizophrenia with milder side effects compared to existing therapies. This approval is seen as a monumental advancement in psychiatric drug development, offering a new option for the estimated 1.8 million people in the U.S. treated for schizophrenia, many of whom cycle through antipsychotics due to limited effectiveness or intolerable side effects.
View original story
Similar markets
Less than 10% • 25%
10% to 19% • 25%
20% to 29% • 25%
30% or more • 25%
Yes • 50%
No • 50%
Less than 20% • 25%
20% to 30% • 25%
31% to 40% • 25%
More than 40% • 25%
Less than $250 million • 25%
$250 million to $499 million • 25%
$500 million to $749 million • 25%
$750 million or more • 25%
Yes • 50%
No • 50%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Negative impact • 25%
No reports • 25%
Mild side effects • 25%
Moderate side effects • 25%
Severe side effects • 25%